Sign In
Buy ALT
$2.92
+0.0500 (+1.74%)
At Close: Jun 04, 2026
Altimmune to Participate at Two Upcoming Investor Conferences
07:30am, Tuesday, 26'th Nov 2024
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will parti
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids
Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge
03:43pm, Wednesday, 13'th Nov 2024
Results from the phase 2b IMPACT study, using Pemvidutide for the treatment of patients with MASH, expected Q2 of 2025. The global metabolic dysfunction-associated steatohepatitis market size is expec
Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health
12:38pm, Wednesday, 13'th Nov 2024
Altimmune, Inc.'s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial for obe
ALT5 Sigma Reports Fiscal Financial Results for Third Quarter 2024
05:23pm, Tuesday, 12'th Nov 2024
Record quarter for ALT5 with Q3 revenue of $4.94 million New customer onboarding strong in Q3 and continuing into Q4 Launching additional capabilities for Alt5 Prime and Alt5 Pay in Q4 2024 and Q1 202
Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript
10:00am, Tuesday, 12'th Nov 2024
Altimmune, Inc. (NASDAQ:ALT ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan, Investor Relations Advisors, Altimmune Vipin Garg - Chief E
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
07:30am, Monday, 11'th Nov 2024
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Office
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Monday, 11'th Nov 2024
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of Director
How Altimmune Could Grab a Big Chunk of the GLP-1 Market
07:46am, Friday, 08'th Nov 2024
As pharma giants Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO are raking in the cash from their weight loss and diabetes drugs, many other companies want a piece of the pie. They're developing treat
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
07:30am, Thursday, 07'th Nov 2024
Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 program Pivotal Phase 3 trials designed to leverage the differentiated attributes of pemvidutide and potential b
ALT5 Sigma Welcomes FinTech Executive, Ron Pitters to Its Board of Directors
08:30am, Wednesday, 06'th Nov 2024
LAS VEGAS, NV / ACCESSWIRE / November 6, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a fintech innovator providing next-generation blockchain-powered technologies for tokeni
Altimmune to Participate at Two Upcoming Investor Conferences
07:30am, Wednesday, 06'th Nov 2024
GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will parti
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
07:30am, Monday, 04'th Nov 2024
GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024 financial res
ALT5 Sigma to Exhibit at Money20/20 October 27-30, 2024
05:00pm, Wednesday, 23'rd Oct 2024
LAS VEGAS, NV / ACCESSWIRE / October 23, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settleme
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024
08:00am, Tuesday, 15'th Oct 2024
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data showing reductions of multiple classes of
